DHR vs MRK: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
Danaher Corporation · Healthcare
$221.12
+29.6% upside to fair value
Med Conviction
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
DHR has more upside to fair value
(+29.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
MRK |
| Current Price |
$221.12 |
$147.17 |
| Fair Value Estimate |
$286.52 |
$141.07 |
| Upside to Fair Value |
+29.6%
|
-4.1%
|
| Market Cap |
$155.4B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
29.6x
|
| Price / Sales |
6.2x
|
5.5x
|
| Price / FCF |
28.5x
|
22.6x
|
| Revenue Growth YoY |
+5.5%
|
+5.1%
|
| Gross Margin |
58.5%
|
75.4%
|
| Operating Margin |
20.4%
|
16.7%
|
| Return on Equity |
7.7%
|
6.6%
|
| Dividend Yield |
0.65% |
2.31% |
| FCF Yield |
3.51%
|
4.42%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high…
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
DHR |
MRK |
| Zone Low |
$214.89 |
$105.80 |
| Zone High |
$243.54 |
$119.91 |
| In Buy Zone? |
Yes
|
No
|